logo
Plus   Neg
Share
Email

Acceleron Pharma's ACE-083 Fails In Phase 2 Study For FSHD

Acceleron Pharma Inc. (XLRN) on Monday said its investigational therapy ACE-083 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.

Although ACE-083 showed a significant increase in mean total muscle volume, which was the primary endpoint of the trial, the secondary endpoint of functional tests was failed. As a result, the company is not planning to continue with further study of ACE-083 for FSHD.

FSHD is a genetic muscle disorder that starts usually before the age of 20. It first affects the muscles of the face, shoulder blades and upper arms by weakening them, and gradually spreads to other muscles.

ACE-083 is also being explored as a potential treatment for Charcot-Marie-Tooth disease—a neuromuscular disorder, and a phase II trial in this indication is underway. Topline results from this trial are expected in the first quarter of the next year.

XLRN closed Monday's trading at $44.65, up 1.71%. In after-hours, the stock was down 6.83% to $41.60.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
SCARPA North America has recalled about 4,200 ski boots due to risk of fall. The company has recalled Maestrale RS and Maestrale Men's ski boots as its shell can crack, posing a fall hazard and risk of injury to the consumer. The recall involves the Fall 2017 Maestrale RS and Maestrale Men's Ski... Walt Disney's (DIS) Frozen 2, the sequel to its 2013 blockbuster, is expected to record a strong domestic opening of over $100 million this weekend. Frozen 2 will become the 10th animated film to debut with over $100 million and the first animated film outside the summer window to hit the mark. Frozen... Indonesia is exploring a total ban on the use of electronic cigarettes and vape products in the country due to healthcare concerns following the lung illness outbreak related to vaping in the U.S., according to reports. However, the South-East Asian country has not reported any cases of vaping-related illness. Chain-smoking Indonesia is the world's second largest tobacco market.
RELATED NEWS
Follow RTT
>